Silo Pharma’s Alzheimer’s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
Silo Pharma (Nasdaq: SILO) announced the publication of preclinical research for its Alzheimer's disease therapeutic SPC-14 in the prestigious journal Alzheimer's Research & Therapy. The study demonstrates that SPC-14, a combination of (R,S)-ketamine with prucalopride, showed promising results in treating cognitive decline in Alzheimer's disease.
The research, co-authored by CEO Eric Weisblum, revealed that SPC-14 improved memory retrieval in mouse models. The therapeutic was developed under a sponsored research agreement with Columbia University, from which Silo obtained an exclusive global license in 2024 for development, manufacturing, and commercialization. The targeted Alzheimer's disease treatment market is projected to reach $30.8 billion by 2033, growing at a 18.8% CAGR.
Silo Pharma (Nasdaq: SILO) ha annunciato la pubblicazione su Alzheimer's Research & Therapy di uno studio preclinico sul suo candidato terapeutico per l'Alzheimer, SPC-14. La ricerca mostra che SPC-14, una combinazione di (R,S)-ketamina e prucalopride, ha dato risultati promettenti nel contrastare il declino cognitivo associato alla malattia.
Lo studio, cofirmato dall'amministratore delegato Eric Weisblum, ha evidenziato che SPC-14 migliora il recupero della memoria in modelli murini. Il composto è stato sviluppato nell'ambito di un accordo di ricerca sponsorizzata con la Columbia University, da cui Silo ha ottenuto nel 2024 una licenza esclusiva globale per lo sviluppo, la produzione e la commercializzazione. Il mercato mirato per i trattamenti dell'Alzheimer è stimato raggiungere 30,8 miliardi di dollari entro il 2033, con un tasso di crescita annuo composto del 18,8%.
Silo Pharma (Nasdaq: SILO) anunció la publicación de una investigación preclínica sobre su terapéutica contra el Alzheimer, SPC-14, en la revista Alzheimer's Research & Therapy. El estudio demuestra que SPC-14, una combinación de (R,S)-ketamina y prucalopride, mostró resultados prometedores en el tratamiento del deterioro cognitivo asociado a la enfermedad.
La investigación, cofirmada por el director ejecutivo Eric Weisblum, reveló que SPC-14 mejoró la recuperación de la memoria en modelos de ratón. La terapia se desarrolló en el marco de un acuerdo de investigación patrocinada con la Universidad de Columbia, de la cual Silo obtuvo en 2024 una licencia global exclusiva para su desarrollo, fabricación y comercialización. Se proyecta que el mercado objetivo para tratamientos del Alzheimer alcance 30.800 millones de dólares para 2033, con un CAGR del 18,8%.
Silo Pharma (나스닥: SILO)는 알츠하이머병 치료제 SPC-14의 전임상 연구 결과가 저명 학술지 Alzheimer's Research & Therapy에 게재되었다고 발표했습니다. 연구는 (R,S)-케타민과 프루칼로프라이드를 결합한 SPC-14가 알츠하이머 관련 인지 저하 치료에 유망한 결과를 보였음을 보여줍니다.
CEO 에릭 바이스블럼(Eric Weisblum)이 공저자로 참여한 연구는 SPC-14가 설치류 모델에서 기억 회복을 향상시켰다고 보고했습니다. 이 치료제는 컬럼비아 대학교와의 후원 연구 계약 하에 개발되었으며, Silo는 2024년에 개발·제조·상업화에 대한 전 세계 독점 라이선스를 확보했습니다. 표적 알츠하이머 치료제 시장은 2033년까지 308억 달러에 도달할 것으로 예상되며, 연평균 성장률은 18.8%입니다.
Silo Pharma (Nasdaq: SILO) a annoncé la publication d'une recherche préclinique sur son traitement contre la maladie d'Alzheimer, SPC-14, dans la revue Alzheimer's Research & Therapy. L'étude montre que SPC-14, une combinaison de (R,S)-kétamine et de prucalopride, a donné des résultats prometteurs pour traiter le déclin cognitif lié à la maladie.
La recherche, co-signée par le PDG Eric Weisblum, a révélé que SPC-14 améliorait la récupération de la mémoire chez des modèles murins. Le traitement a été développé dans le cadre d'un accord de recherche sponsorisé avec l'université Columbia, dont Silo a obtenu en 2024 une licence mondiale exclusive pour le développement, la fabrication et la commercialisation. Le marché ciblé des traitements contre l'Alzheimer devrait atteindre 30,8 milliards de dollars d'ici 2033, avec un TCAC de 18,8 %.
Silo Pharma (Nasdaq: SILO) gab die Veröffentlichung präklinischer Forschungsergebnisse zu seinem Alzheimer-Wirkstoff SPC-14 in der Fachzeitschrift Alzheimer's Research & Therapy bekannt. Die Studie zeigt, dass SPC-14, eine Kombination aus (R,S)-Ketamin und Prucaloprid, vielversprechende Ergebnisse bei der Behandlung des kognitiven Abbaus bei Alzheimer erzielt.
Die gemeinsam mit CEO Eric Weisblum verfasste Forschung ergab, dass SPC-14 die Gedächtnisabrufleistung in Mausmodellen verbesserte. Der Wirkstoff wurde im Rahmen einer finanzierten Forschungsvereinbarung mit der Columbia University entwickelt, von der Silo 2024 eine exklusive weltweite Lizenz für Entwicklung, Herstellung und Vermarktung erwarb. Der adressierbare Markt für Alzheimer-Therapien wird bis 2033 voraussichtlich 30,8 Milliarden US-Dollar erreichen und mit einem CAGR von 18,8 % wachsen.
- Successful publication in a leading peer-reviewed scientific journal validates research credibility
- Preclinical results showed improved cognitive decline and memory retrieval in mouse models
- Exclusive global license agreement with Columbia University for SPC-14
- Large market opportunity with Alzheimer's treatment market projected to reach $30.8B by 2033
- Still in preclinical stage with studies only conducted in mouse models
- Further clinical trials and FDA approval required before commercialization
Insights
Silo's Alzheimer's candidate SPC-14 shows promising preclinical results in mice, validating their approach to targeting cognitive decline.
The publication of SPC-14's preclinical research in Alzheimer's Research & Therapy represents a significant scientific validation milestone for Silo Pharma's approach. The study demonstrates that the combined administration of (R,S)-ketamine with prucalopride improved cognitive decline specifically by enhancing memory retrieval in a fear conditioning mouse model. This combination creates a novel multi-modal therapeutic strategy by simultaneously targeting NMDA receptors and serotonin 5-HT4 receptors.
From a mechanistic perspective, this dual-targeting approach is particularly intriguing. NMDA receptor modulation has long been studied for potential cognitive benefits, while 5-HT4 receptor activation has shown promise in enhancing memory formation. The combinatorial approach suggests potential synergistic effects that could address the complex pathophysiology of Alzheimer's disease more effectively than single-target approaches.
The progression from preclinical mouse models to human trials remains a significant hurdle, with many promising Alzheimer's candidates failing in later-stage development. However, publication in a peer-reviewed journal adds credibility to Silo's research methodology and findings. The exclusive global license agreement with Columbia University further strengthens Silo's intellectual property position for this candidate.
The projected market growth for Alzheimer's treatments (
Manuscript featured in leading open-access scientific journal Alzheimer’s Research & Therapy
SARASOTA, FL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced the publication of preclinical research for its Alzheimer’s disease (AD) therapeutic, SPC-14, in Alzheimer’s Research & Therapy, an international open-access peer-reviewed scientific journal known as the major forum for translational research into AD.
The study, titled “Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer’s disease,” details research methods and results indicating that the combined administration of (R,S)-ketamine with prucalopride is a novel multi-modal therapeutic strategy to treat cognitive decline in AD. The Company’s CEO, Eric Weisblum, was a co-author of the study and the project was supported by a sponsored research program from the Company.
“The results of this study showed that the SPC-14 formulation improved cognitive decline by increasing memory retrieval in a fear conditioning model in mice. The conclusion identifies SPC-14 as a promising drug combination for therapeutic use in AD and contributes to advancements in discovering targeted therapies for the treatment of dementia in AD,” said Silo CEO Eric Weisblum.
SPC-14 was developed under a sponsored research agreement with Columbia University. In 2024, Silo entered into an exclusive global license agreement with Columbia University under which it is authorized to further develop, manufacture, and commercialize SPC-14.
SPC-14 addresses a vast Alzheimer’s disease treatment market projected to grow to
About SPC-14
SPC-14 is a novel intranasal therapeutic that targets glutamate receptor NDMAR and serotonin type 4 receptor 5HT4 to treat cognitive and neuropsychiatric symptoms in Alzheimer’s disease. In the latest small animal preclinical study, SPC-14 was effective against LH (luteinizing hormone) stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia, a measure of anxiety.
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
1 Market.us, Alzheimer’s Disease Therapeutics Market Value to Reach USD 30.8 Billion by 2033 | Driven by the Advancements in Neurological Research. January 2024.
FAQ
What are the key findings of Silo Pharma's (SILO) SPC-14 Alzheimer's study?
What is the market potential for Silo Pharma's (SILO) Alzheimer's treatment?
Who developed Silo Pharma's SPC-14 Alzheimer's therapeutic?
Where was Silo Pharma's (SILO) Alzheimer's research published?
What stage of development is Silo Pharma's (SILO) SPC-14 in?
